Month: September 2026

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization

BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R. Duane Clark II and James Sapirstein, R.Ph., MBA, to its Board of Directors. The appointments add commercial and strategic operating expertise as INmune Bio prepares Ebstrocel™ for potential rare-disease commercialization and pursues business-development and partnering opportunities across its pipeline.

Mr. Clark brings more than 40 years of global pharmaceutical and biotechnology leadership, with particular depth in rare diseases, immunology and specialty-product commercialization. He currently serves as General Manager, U.S. Rare Diseases at Sanofi, where he leads a multi-billion-dollar business spanning seven rare-disease brands with full profit-and-loss responsibility. His experience includes multiple product launches, market-access strategy, M&A integration, and leadership across sales, marketing, medical and commercial operations. Earlier in his career, he led Sanofi’s U.K. and Ireland multiple sclerosis business and held commercial and business-development roles at CTI Clinical Trial & Consulting Services, Encysive Pharmaceuticals, Astellas Pharma, Ortho Biotech and Marion Laboratories.

Mr. Sapirstein brings more than 40 years of biopharmaceutical leadership spanning business development, licensing, commercialization, capital formation and public-company leadership experience. He has led six global commercial product launches and participated in more than 20 additional launches. His career includes senior roles at Gilead Sciences, Bristol Myers Squibb, Hoffmann-La Roche, Eli Lilly and Serono Laboratories. He also founded and led Tobira Therapeutics, which was later acquired by Allergan in a transaction with total potential consideration of up to approximately $1.7 billion, including contingent milestone payments. Mr. Sapirstein also brings extensive experience structuring strategic transactions and guiding biotechnology companies through growth, restructuring, and value-creating exits.

“These appointments bring capabilities directly aligned  with INmune Bio’s next stage of growth,” said David Moss, Chief Executive Officer of INmune Bio. “Duane’s rare-disease leadership leading a major rare-disease business will strengthen our planning for market access and potential commercialization of Ebstrocel. James’s business development, licensing, and financing experience will support our evaluation of strategic opportunities for our broader pipeline. Together, they add practical experience to help us translate development progress into potential patient and shareholder value.”

The new directors strengthen the Board in:

• Rare-disease commercialization: Guide market access and pricing, patient identification, commercial infrastructure and launch execution for Ebstrocel™ in recessive dystrophic epidermolysis bullosa (RDEB) and potential additional rare-disease indications.
• Business development and strategic transactions: Strengthen the evaluation and negotiation of licensing, distribution, co-development and other strategic relationships intended to accelerate development and broaden commercial reach.
• Commercial scale and execution: Help align clinical, regulatory, manufacturing and commercial functions as INmune Bio advances from late-stage development toward potential product launches.

“Ebstrocel has the potential to address important unmet needs in rare disease, and INmune Bio is approaching the stage at which disciplined launch and market-access planning can become a meaningful competitive advantage,” said Mr. Clark. “I look forward to helping the Company build a patient-focused commercialization strategy and the capabilities required to execute it.”

“INmune Bio has multiple opportunities to create value through focused internal development and well-structured strategic partnerships,” said Mr. Sapirstein. “I look forward to contributing my business-development, transaction and commercialization experience as the Company evaluates the best path to advance its differentiated platforms.”

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

• CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.

• XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including  Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:

David Moss 
Chief Executive Officer 
(561) 710-0512 
info@inmunebio.com

Daniel Carlson 
Head of Investor Relations 
(415) 509-4590 
dcarlson@inmunebio.com

SANTA MONICA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — The Macerich Company (NYSE: MAC) today announced that Jackson Hsieh, President and Chief Executive Officer, Dan Swanstrom, Senior Executive Vice President and Chief Financial Officer and Treasurer, and Doug Healey, Senior Executive Vice President Leasing, will present to and speak with investors at BofA Securities 2026 Global Real Estate Conference in New York, NY September 15-16, 2026.

Macerich will present at 12:45 p.m. Eastern on Wednesday, September 16, 2026. The live audio webcast and a copy of the presentation can be accessed from the Company’s website at https://investing.macerich.com. The webcast replay will be available within 24 hours after conclusion of the live event and available at the same location for one year.

About Macerich
Macerich (NYSE: MAC) is a fully integrated, self-managed, self-administered real estate investment trust (REIT). As a leading owner, operator, and developer of high-quality retail real estate in densely populated and attractive U.S. markets, Macerich’s portfolio is concentrated in California, the Pacific Northwest, Phoenix/Scottsdale, and the Metro New York to Washington, D.C. corridor. Developing and managing properties that serve as community cornerstones, Macerich currently owns approximately 40 million square feet of real estate, consisting primarily of interests in 38 retail centers.
 
Macerich uses, and intends to continue to use, its Investor Relations website, which can be found at investing.macerich.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Additional information about Macerich can be found through social media platforms such as LinkedIn. Reconciliations of non-GAAP financial measures, including NOI and FFO, to the most directly comparable GAAP measures are included in the earnings release and supplemental filed on Form 8-K with the SEC, which are posted on the Investor Relations website at investing.macerich.com.

INVESTOR CONTACT: Investor Relations, IR@macerich.com

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce that its fully permitted Goldboro Gold Project in Nova Scotia has been selected for inclusion in the Canada Investment Summit Prospectus, which will be given to leading global investors at the inaugural Canada Investment Summit, hosted by Prime Minister Mark Carney in partnership with CPP Investments and PSP Investments, in Toronto on September 14-15, 2026.

Kevin Bullock, President, CEO & Director of NexGold, commented: “I am honoured on behalf of NexGold to see the Goldboro Gold Project showcased in the Canada Investment Summit Prospectus, which will be presented to some of the world’s largest long-horizon institutional investors and prominent business leaders. Goldboro’s inclusion in the Summit Prospectus speaks not only to the quality of the Project from an investment standpoint but is also a testament to the hard work of our team in advancing the Project, while building strong relationships with local communities and First Nations. As a Canadian company advancing a portfolio of Canadian projects toward production, we are proud to have the Goldboro Gold Project featured among the projects highlighted at this high-profile global event.”

About the Goldboro Gold Project

NexGold is steadily advancing its fully permitted Goldboro Gold Project in Nova Scotia. The Company is evaluating a potential construction decision for Goldboro, which is currently anticipated in 2026. The Goldboro Gold Project is located in Guysborough County, Nova Scotia, approximately 1.6 km north of the Village of Goldboro. Situated along Route 316, the Project benefits from access to world class infrastructure, services and a skilled workforce, supporting efficient future development activities. Based on the Project’s 2022 Mineral Resource Estimate, Goldboro contains an estimated 2.58 million ounces of gold within 21.6 million tonnes grading 3.72 g/t gold. According to the Goldboro Feasibility Study, the Project is expected to have a mine life of approximately 11 years and average annual gold production of approximately 100,000 ounces during the initial years of operation, with potential opportunities for future expansion.

About the Canada Investment Summit

The inaugural Canada Investment Summit will take place in Toronto on September 14-15, 2026. Hosted by the Prime Minister of Canada in partnership with CPP Investments and PSP Investments, the Summit will convene the world’s largest investors, including top CEOs, entrepreneurs, and prominent global business leaders for a two-day forum focused on long-horizon capital, commercial opportunities and productive assets that strengthen Canada’s growth and economic resilience. The Summit forms part of the Government of Canada’s broader effort to strengthen Canada’s investment environment, diversify trade and attract approximately $1 trillion in total investment in Canada over the next five years.

For additional information on the Canada Investment Summit: Canada Investment Summit 2026.

Qualified Person

Paul McNeill, P.Geo., VP Exploration of NexGold, and a “Qualified Person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical information contained in this news release.

About NexGold Mining Corp.
NexGold is a gold-focused company with assets in Canada and Alaska, including the Goldboro Gold Project in Nova Scotia, the Goliath Gold Complex (which includes the Goliath, Goldlund and Miller deposits) in Northwestern Ontario, and additional exploration projects across Canada. NexGold also holds a 100% interest in the high-grade Niblack copper-gold-zinc-silver VMS project in southeast Alaska. NexGold is committed to ongoing, meaningful engagement with regional communities and Indigenous Nations to support sustainable development, safe operations, and shared economic and social benefits.

Further details about NexGold, including a Feasibility Study for the Goldboro Gold Project and a Prefeasibility Study for the Goliath Gold Complex, are available under the Company’s issuer profile on www.sedarplus.ca and on NexGold’s website at www.nexgold.com.

Contact:

Kevin Bullock President & CEO (416) 214-4654 kbullock@nexgold.com	Greg DiTomaso Investor Relations (647) 547-5357 gditomaso@nexgold.com

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of applicable U.S. securities laws (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements regarding: the advancement and development of the Goldboro Gold Project; the timing of a potential construction decision; future construction, financing and development activities; the Project’s anticipated mine life and production profile; potential future expansion opportunities; the Company’s participation in, and potential benefits arising from, the Canada Investment Summit; and the Company’s plans, objectives and expectations for its projects. All statements, other than statements of historical fact, are forward-looking.

Forward-looking information is often, but not always, identified by the use of words and phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “projects”, “anticipates”, “believes”, “targets”, “potential”, “may”, “could”, “should”, “would”, “will” and similar expressions.

Forward-looking information is based on a number of assumptions, including, among others, assumptions regarding financing availability, commodity prices, operating and capital cost estimates, market conditions, the timing of regulatory, corporate and Board approvals, the continued advancement of the Goldboro Gold Project, and the accuracy of technical studies and Mineral Resource estimates. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others: the ability of the Company to obtain financing on acceptable terms or at all; risks associated with the development and construction of mineral projects; changes in commodity prices and market conditions; operating and capital cost increases; environmental, community, Indigenous, permitting and regulatory risks; delays in obtaining approvals or completing development activities; labour shortages; and the other risks described in the Company’s public disclosure documents, including its Management’s Discussion and Analysis for the year ended December 31, 2025, available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Although the Company believes that the assumptions and expectations reflected in the forward-looking information are reasonable, there can be no assurance that such information will prove to be accurate, as actual results and future events may differ materially from those anticipated. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is provided to assist investors in understanding the Company’s current expectations, plans and objectives and may not be appropriate for other purposes. The Company undertakes no obligation to update or revise any forward-looking information, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

• CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed

• CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile
   
• Data support CRB-913’s potential to establish a new class of oral non-incretin obesity medicines

• Data selected for late-breaking presentation at ObesityWeek® 2026

• Company will hold an investor call at 8:00am EDT today

NORWOOD, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) —  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced positive topline data from the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The data demonstrated statistically significant and clinically meaningful weight loss at all three doses with the 60 mg dose achieving a mean weight loss of 5% at 12 weeks. CRB-913 was associated with a favorable safety profile and fewer gastrointestinal (GI) adverse events based on cross-trial comparison with published data of currently marketed oral GLP-1 drugs. These data support CRB-913’s potential to establish a new class of oral, non-incretin obesity medicines.

“From a clinical practice perspective, a substantial number of patients with obesity either cannot tolerate GLP-1 receptor agonists or do not achieve an adequate therapeutic response,” said Harold Bays, M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center/Monroe Biomedical Research, Clinical Associate Professor at the University of Louisville School of Medicine, and an investigator on the CANYON-1 trial. “In addition, more than 60% discontinue treatment within the first year. What I find particularly encouraging about the CANYON-1 study results is that weight reduction had not yet plateaued by the end of the 12-week treatment period, and that CRB-913 appears to have avoided the depressive effects associated with earlier central nervous system-acting cannabinoid receptor agonists. These findings support the potential emergence of the first agent in a new class of obesity medications, offering a novel mechanism of action to help treat the global epidemic of obesity.”

Yuval Cohen, Ph.D., CEO of Corbus Pharmaceuticals, added, “We set out to test a key hypothesis: by successfully designing a peripherally restricted CB1 inverse agonist, can we deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s? The CANYON-1 data provide an important confirmatory milestone of this hypothesis. We are excited about these results and look forward to the Phase 2 study of CRB-913.”

Study Design
The CANYON-1 Phase 1b clinical trial was a 16-week double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (NCT07310901). The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily as well as a placebo cohort (randomization of 1:1:1:1). A dose titration regimen was used with all participants receiving CRB-913 commencing at 20 mg/day and then titrating up every two weeks to either 40 mg/day or 60 mg/day depending on their assigned cohort. Participants were dosed for 12 weeks and followed for an additional 4 weeks.

Topline Efficacy
CRB-913 demonstrated rapid, statistically significant and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses.

Cohort	Placebo (n=66)		CRB-913
			20 mg (n=65)		40 mg (n=61)		60 mg (n=62)
LS Mean % change in  weight loss from baseline at week 121	0.0	%	2.8	%	3.3	%	5.0	%
LS Mean % change in weight loss at week 121 (placebo adjusted)	NA		2.8	%	3.3	%	5.0	%
p-value vs. placebo	NA		<0.0001		<0.0001		<0.0001

_{¹ Efficacy estimand. The LS means, and p-values are the Mixed Model for Repeated Measures (MMRM) with percent change from baseline as the dependent variable; sex, treatment group, visit and treatment group-by-visit interaction as categorical fixed effects, and the baseline weight as a covariate. An unstructured covariate matrix is used.}

Weight loss response rates were significantly higher across all three CRB-913 cohorts compared to the placebo cohort. All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline. Similarly, 6.7% of the participants in that cohort lost more than 7.5% of their weight from baseline. The highest recorded weight loss for this cohort was 13.4% from baseline.

Topline Safety and Tolerability²
CRB-913 was generally safe and well tolerated. Treatment discontinuations due to AEs with CRB-913 (3.1%-13.1%) were in line with those recorded with approved oral GLP-1s (6.9%-20.7%) and markedly less than the 13%-42% study discontinuation rate reported with monlunabant.

Psychiatric AEs of Special Interest:
Treatment emergent psychiatric AEs were infrequent, mild to moderate, and transient. There were no serious or severe psychiatric AEs reported in the study. There were no cases of suicidality and only one case of transient depressive symptom (moderate) out of a total of 188 participants dosed with CRB-913. Psychiatric AEs were noted across all cohorts, including placebo, and generally showed no dose-related patterns. The most common psychiatric AE was irritability, and all cases were mild.

Psychiatric AEs were broadly in line with those reported for clinical studies for liraglutide, semaglutide and tirzepatide. The psychiatric AEs were lower than those seen with monlunabant, a recently studied but subsequently discontinued CB1 inverse agonist with significantly higher brain penetration than CRB-913.

Psychiatric Treatment Emergent Adverse Events

	Placebo (n=66)	CRB-913 20 mg (n=65)	CRB-913 40 mg (n=61)	CRB-913 60 mg (n=62)	Published data for liraglutide3, semaglutide4 and tirzepatide5	Monlunabant6 Phase 2 (n=180)
Depression	0%	0%	0%	1.6%	2%-4.6%	3%-8%
Anxiety	4.5%	3.1%	8.2%	4.8%	1.9%-7.2%	10%-27%
Irritability	0%	6.2%	8.2%	9.7%	Not reported	10%-17%
Insomnia	3.0%	1.5%	4.9%	0%	2.9%-3.9%	7%-17%

_{² These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. Published safety data reflect adverse events reported over study durations longer than the 12-week CANYON-1 treatment period: 56-week study (liraglutide, Diabetes Obes Metab. 2017), 68-week study (semaglutide, JAMA Intern Med. 2024), and 72-week study (tirzepatide, Obesity 2026).}

_{³ O’Neil et al. “Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 (link)}

_{⁴ Wadden et al. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Intern Med. 2024 (link)}

_{⁵ Wadden et al, “Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT,” Obesity 2026 (link)}

_{⁶ Knop, F.K. et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet 2025 (link)} 

Gastrointestinal AEs of Special Interest:
GI AEs were mild or moderate across all CRB-913 doses, with no serious or severe cases reported and were generally not dose-dependent. The emerging GI profile appears more tolerable than the oral GLP-1 class with markedly less vomiting, constipation, and nausea.

Gastrointestinal Treatment Emergent Adverse Events

	CRB-913 (20 mg) (n=65)		CRB-913 (40 mg) (n=61)		CRB-913 (60 mg) (n=62)		Oral semaglutide (25 mg)7		Orforglipron (36 mg capsule)8
Vomiting	4.6	%	8.2	%	1.6	%	31	%	14% – 28%
Nausea	15.4	%	26.2	%	22.6	%	47	%	41% – 48%
Constipation	4.6	%	1.6	%	4.8	%	20	%	24% – 28%
Diarrhea	21.5	%	26.2	%	22.6	%	18	%	3% –14%

_{Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. Published safety data reflect adverse events reported over study durations longer than the 12-week CANYON-1 treatment period: 68-week study (oral semaglutide 25 mg, N Engl J Med 2025) and 36-week study (orforglipron, N Engl J Med 2023).}

_{⁷ Wharton, S. et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; N Engl J Med 2025 (Link)}

_{⁸ Wharton S, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link). Note: Early clinical development evaluated a 36mg capsule formulation; subsequent bridging established pharmacokinetic bioequivalence to the 17.2mg tablet commercial formulation.}

Next Steps
The data from the CANYON-1 Phase 1b trial will be detailed in a late-breaking presentation at ObesityWeek® 2026, to be held November 14 – 17, 2026. The Company plans to engage with the FDA on the clinical development plan and expects to initiate a Phase 2 monotherapy study in the first half of 2027. In addition, the Company is evaluating the potential to combine CRB-913 with GLP-1 therapy.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated timing for initiation of clinical trials, anticipated regulatory interactions and outcomes, including alignment with FDA on trial design, potential accelerated approval, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway  and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025, and other filings we make with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) announced that its wholly-owned Brazilian subsidiary, Belo Sun Mineração Ltda. (“Belo Sun Mineração”), was formally notified on September 11, 2026, of a request for suspension of provisional relief (Suspensão de Tutela Provisória, or “STP”) filed by Brazil’s Federal Public Prosecutor’s Office (“MPF”) before the Brazilian Supreme Court (“STF”), concerning the Installation License (“LI”) for the Company’s Volta Grande Gold Project (the “Project”) in Pará, Brazil.

The STP proceeding (STP 1.156/PA) seeks to immediately suspend the judicial decision issued by the Federal Regional Court of the 1st Region (“TRF-1”) on February 13, 2026, in Interlocutory Appeal No. 1004658-74.2026.4.01.0000, which reinstated the LI and authorized the resumption of regular installation activities. The decision found that the Company had demonstrated compliance with the applicable judicial requirements, including completion of an Indigenous Component Study (“ECI”) based on primary data and consultation under the applicable protocol. The MPF also seeks the continuation of that suspension until a final and non-appealable judgment is rendered in the underlying civil public action concerning the ECI.

STF President Justice Edson Fachin issued an order dated September 2, 2026 and directed Belo Sun Mineração, the State of Pará, the Federal Government, FUNAI and the Municipality of Senador José Porfírio to respond within a common 72-hour deadline. The State of Pará and Belo Sun have already filed their response, requesting that the STP be denied.

Clovis Torres, Chief Executive Officer of Belo Sun commented: “We remain confident in the strength and validity of our Installation License. The TRF-1 court reinstated the license after confirming that we fully satisfied all judicial conditions, including completing the Indigenous Component Study with primary data and carrying out transparent consultations. These are facts which have been previously acknowledged by FUNAI. A STP is an exceptional procedural remedy that requires a showing of a concrete risk of serious harm to public order, health, safety or the economy. As we continue working collaboratively through the conciliation process, we see no basis for such an emergency suspension and will vigorously defend the project and validity of the Installation License.”

The STF is expected to rule on the interim request after receiving the responses from the parties and interested entities formally notified in the proceeding, followed by a submission from the Prosecutor General’s Office.

The LI remains reinstated and in effect while the STF considers the submissions.

About the Company

Belo Sun is a Canadian-based mining company with a portfolio of gold-focused properties in Brazil. The Company is currently focused on the development of the Volta Grande Gold Project. Belo Sun trades on the Toronto Stock Exchange under the symbol “BSX” and on the OTCQX under the symbol “BSXGF”.

For more information, please visit www.belosun.com or contact Investor Relations at info@belosun.com or 1-888-516-4171.

Caution regarding forward-looking information:

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, the continued advancement of the Project, the Company’s and interested parties’ responses to the STP filed by the MPF and timelines for responses and rulings imposed by the STF, conciliation process with FUNAI and the ongoing review and update of the Project’s studies. Forward-looking information is based on the opinions and estimates of management as of the date such information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. These factors include, without limitation, actions by the MPF and other parties, rulings or orders of the STF or other courts, changes in the regulatory environment, risks related to the ability of the Company to attract and retain qualified personnel, the ability of the Company to advance the Project to the construction phase, and other risks described in the Company’s filings with Canadian securities regulatory authorities, including the Company’s most recent Annual Information Form. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo Silver” or the “Company”) (TSX-V: APGO | OTCQB: APGOF | Frankfurt: 6ZF) today reaffirmed its support for Ejido Benito Juárez (the “Ejido”) in addressing the water challenges that affect agriculture, livestock and livelihoods on its lands in Chihuahua, Mexico. The Company has expressed its commitment to working with the Ejido over the long term on practical solutions to those challenges, beginning with independent technical work on the aquifer, the springs and the existing wells.

“Water is the first question at Ejido Benito Juárez, and it should be,” said Tom Peregoodoff, Executive Chair of Apollo Silver. “The wells and springs of Ejido Benito Juárez have sustained families and their farmland for generations. We have agreed to present the Ejido with a plan outlining our long-term commitment to advancing solutions to their water challenges, including direct support for their agriculture and their livestock.”

The scope, the priorities and the sequencing of the water program will be defined jointly with the Ejido and in accordance with applicable authorizations. The assembly resolution reinstating mineral exploration at Cinco de Mayo is in process; pending that resolution taking effect, Apollo Silver will continue to meet with the community and its representatives ahead of any significant field activity.

Apollo Silver also notes the position of President Claudia Sheinbaum’s administration that mining remains an important contributor to the Mexican economy and that water is to be treated as a right of the communities that depend on it, reflected in the reforms to Mexican water law. The Company believes both propositions can be true at the same time, and intends that community water be part of the resolution wherever it operates.

About Apollo Silver Corp.

Apollo Silver Corp. is a mineral exploration and development company advancing the Calico Silver Project in San Bernardino County, California, and holds an earn-in interest in the Cinco de Mayo Project in Chihuahua, Mexico. The Company is listed on the TSX Venture Exchange under the symbol APGO, on the OTCQB under the symbol APGOF and on the Frankfurt Stock Exchange under the symbol 6ZF.

Please visit www.apollosilver.com for further information.

ON BEHALF OF THE BOARD OF DIRECTORS

Thomas Peregoodoff
Executive Chair

For further information, please contact:

Email: info@apollosilver.com
Telephone: +1 (604) 428-6128

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information

This news release includes “forward-looking statements” and “forward-looking information” within the meaning of Canadian securities legislation. All statements included in this news release, other than statements of historical fact, are forward-looking statements including, without limitation, statements with respect to the Company’s intention to work with the Ejido over the long term on practical solutions to water challenges affecting agriculture, livestock and livelihoods; the timing, scope and results of independent technical work on the aquifer, springs and existing wells; the Company’s intention to present the Ejido with a plan outlining its long-term commitment to water solutions and direct support for agriculture and livestock; the anticipated joint definition of the scope, priorities and sequencing of the water program; the timing and outcome of the assembly resolution reinstating mineral exploration at Cinco de Mayo; the Company’s plans to continue meeting with the community and its representatives ahead of any significant field activity; the anticipated interaction between Mexican federal water and mining policy and the Company’s operations; and the Company’s future plans, strategies, and objectives. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, “potential”, “target”, “budget” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions and includes the negatives thereof.

Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated, including but not limited to: the outcome and timing of the assembly resolution reinstating mineral exploration at Cinco de Mayo; the ability to reach mutually acceptable arrangements with the Ejido regarding water solutions, or at all; changes in Mexican federal or state water and mining laws or policy; community and stakeholder relations; risks inherent in mineral exploration; uncertainty of mineral resource estimates; fluctuations in commodity prices; regulatory and permitting risks; title risks; and general economic and market conditions. Forward-looking information is based on reasonable assumptions that have been made by the Company as at the date of such information and is subject to known and unknown risks, uncertainties and other factors that may have caused actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: risks associated with mineral exploration and development; metal and mineral prices; availability of capital; accuracy of the Company’s projections and estimates; realization of mineral resource estimates, interest and exchange rates; competition; stock price fluctuations; availability of drilling equipment and access; actual results of current exploration activities; government regulation; political or economic developments; environmental risks; insurance risks; capital expenditures; operating or technical difficulties in connection with development activities; personnel relations; and changes in Project parameters as plans continue to be refined. Forward-looking statements are based on assumptions management believes to be reasonable, including but not limited to the price of silver, gold and barite; the demand for silver, gold and barite; the ability to carry on exploration and development activities; the timely receipt of any required approvals; the ability to obtain qualified personnel, equipment and services in a timely and cost-efficient manner; the ability to operate in a safe, efficient and effective matter; and the regulatory framework regarding environmental matters, and such other assumptions and factors as set out herein. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate and actual results, and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information contained herein, except in accordance with applicable securities laws. The forward-looking information contained herein is presented for the purpose of assisting investors in understanding the Company’s expected financial and operational performance and the Company’s plans and objectives and may not be appropriate for other purposes. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients

Brings Eversense 365 to the growing community of iLet Bionic Pancreas users

Plan for commercial launch of the integrated system in Q4 2026

GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world’s first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions. The companies are collaborating to integrate Eversense^® 365 CGM with Beta Bionics’ iLet^® Bionic Pancreas automated insulin delivery (AID) system designed to simplify diabetes management. The integrated device will aim to provide people with diabetes a world-class, truly differentiated AID experience, combining year-long, exceptionally accurate glucose sensing¹ with fully adaptive insulin delivery technology that does not require carb counting* and autonomously determines and delivers user insulin doses.

Eversense 365’s unique implantable design, consistent performance over an entire year², and reduced device burden make it well-suited for AID systems, helping users focus less on their diabetes management technology and more on living their lives — and giving even more people with diabetes the freedom to choose the AID experience that best fits their lives.

“Our Eversense 365 is redefining the CGM market with long-term implantable technology designed to empower better diabetes management and reduce device burden. This collaboration with Beta Bionics will expand our reach to a greater population of people to enable them to manage their diabetes with the most advanced technologies available today,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “We are excited to be working with Beta Bionics on integrating Eversense 365 with the iLet Bionic Pancreas to give more people with diabetes a differentiated AID option and greater choice in finding the experience that is right for them. Building on the early success from our first pump integration, we believe the combination of year-long glucose sensing and advanced automated insulin delivery offers compelling, differentiated benefits for people with diabetes and expands the choices available to them within the AID category.”

Senseonics expects development of the Eversense 365-iLet integration to be completed during the fourth quarter of 2026. Commercial launch is planned following completion of integration activities in the fourth quarter of 2026, subject to required testing, validation activities and applicable regulatory requirements.

Individuals interested in learning more about the integrated Eversense 365 and iLet system, including information on early access opportunities, can sign up to receive updates.

*User must be carb aware.

About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the design, development and commercialization of glucose monitoring products to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense^® 365 and Eversense^® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

For more information, visit www.senseonics.com.

About Eversense^® 365
The Eversense Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and up to 180 days for Eversense E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense 365 and one time per day after day 21 for Eversense E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more.

For important safety information, see https://www.eversensediabetes.com/safety-info/.

Forward Looking Statements

Any statements in this press release about the expectations regarding potential impact on, benefits to, experience of, expanded options for, or outcomes for people with diabetes’ and providers’, statements regarding the results, success and timeline for completion or commercial launch of the integration, statements regarding product’s reach or market impact, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of Eversense 365, uncertainties inherent in the coordination with third parties and new partners and joint work to complete the project, uncertainties inherent in the development of new technologies, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

Senseonics Media Contact
Tim Stamper
FTI Consulting
Tim.Stamper@senseonics.com / Senseonics@fticonsulting.com

Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

______________________
¹ Senseonics. (2026) Eversense 365 Continuous Glucose Monitoring System User Guide. LBL-7702-01-001
² Kaufman F, Jain I, Han S, Mdigini C: Real-World Data from U.S. Commercial Users of the 365-Day Implantable Eversense Continuous Glucose Monitoring System, Including with the twiist AID System Integration. Diabetes Technology & Therapeutics, 8 September 2026; https://doi.org/10.1177/15209156261486125

Board to recommend that shareholders approve renaming the Company Milk Makeup plc

• The Company’s Board of Directors has approved the voluntary delisting of the Company’s Class A Ordinary Shares and Warrants from Nasdaq and the deregistration of those securities under the Exchange Act.
• Company expects to file a Form 25 with the SEC on or about September 24, 2026; delisting expected to become effective on or about October 4, 2026, with the last day of trading on Nasdaq expected to be October 2, 2026.
• Following completion of the sale of Obagi Medical, Waldencast is a single-brand company; shareholders will be asked at an Extraordinary General Meeting to approve renaming the Company Milk Makeup plc. If approved, the Company intends to seek to have its Class A Ordinary Shares quoted in an over-the-counter market under a new ticker symbol “MLKM”.

LONDON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”) today announced that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to voluntarily delist its Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”), and its redeemable warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share (the “Warrants”), from Nasdaq and to deregister such securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

The Company intends to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) to remove its Class A Ordinary Shares and Warrants from listing on Nasdaq on or about September 24, 2026, and as a result, Waldencast expects that the last trading day of its Class A Ordinary Shares and Warrants on Nasdaq will be on or about October 2, 2026. Thereafter, on or about October 5, 2026, the Company intends to file a Form 15 (Certification and Notice of Termination of Registration) with the SEC to suspend the Company’s reporting obligations under Sections 12(g) and 15(d) of the Exchange Act. Upon filing of the Form 15, the Company’s obligation to file periodic reports with the SEC, including Annual Reports on Form 20-F and Current Reports on Form 6-K, will be suspended immediately. The Section 12(b) deregistration is expected to become effective 90 days after the Form 25 filing.

The decision to delist and deregister the Class A Ordinary Shares and Warrants was approved by the Board of Directors of the Company (the “Board”) following an evaluation of a range of factors, including, among others:

• The direct and indirect costs of maintaining a Nasdaq listing and U.S. public reporting status (including audit, legal, advisory, insurance, transfer agent and compliance costs), which have become disproportionate to the size of the Company following the divestiture of Obagi Medical.
• The substantial demands that public company reporting, including compliance with Section 404 of the Sarbanes-Oxley Act, places on senior management’s time and on the Company’s finance organization – time the Board believes is better directed to building the Milk Makeup brand.
• The limited trading volume in, and limited public float of, the Company’s Class A Ordinary Shares, and the concentration of the Company’s share register, which the Board believes have not delivered the liquidity, research coverage or valuation benefits that a public listing is intended to provide.
• The Board’s assessment that the Company’s capital structure and financing needs no longer depend on access to the U.S. public equity markets following the full debt paydown with the proceeds from the Obagi Japan trademark sale and the Obagi Medical divestiture.
• The alternatives available to the Company and the Board’s conclusion that the expected cost savings and operational focus outweigh the reduction in liquidity and public information that will result. In the year ended December 31, 2025, the Company incurred central headquarters costs of $18.5 million. The Board expects that a substantial portion of those costs will be eliminated following the delisting and deregistration.

The Board considered the interests of all shareholders, including minority holders, in reaching this decision, and consulted with its financial and legal advisors.

Subject to shareholder approval, the Board has resolved to recommend that the Company be renamed Milk Makeup plc, so that the corporate identity of the Company aligns with its sole operating brand following completion of the sale of Obagi Medical. A change of name requires approval by special resolution under the Company’s Articles of Association and Jersey law. The Company intends to convene an Extraordinary General Meeting in the coming weeks, and a notice of meeting and accompanying materials will be made available to shareholders in accordance with the Company’s Articles of Association. The delisting and deregistration described above are not conditional on approval of the change of name, and the Company intends to proceed on the timetable set out in this announcement regardless of the outcome of the vote.

Following the delisting of the Company’s Class A Ordinary Shares and Warrants from trading on Nasdaq, the Company intends to seek to have its Class A Ordinary Shares quoted in an over-the-counter market under the ticker “MLKM”, where it intends to publish annual audited financial statements. There is no guarantee, however, that trading of the Company’s Class A Ordinary Shares will occur in an over-the-counter market or otherwise.

Separately, any further allocation of transaction proceeds from the sale of Obagi Medical to Bridgepoint, completed on July 30, 2026, remains subject to review by the Board.

The Company reserves the right to postpone or withdraw the above filings prior to their effectiveness; if necessary, the Company will make any further announcements as required by the Nasdaq listing standards and other applicable laws.

The Company expects to publish a trading update for the six months ended June 30, 2026, and comparable periods in the coming weeks.

About Waldencast

Waldencast plc (NASDAQ: WALD) is the parent company of Milk Makeup, the clean prestige beauty brand born from the creative community of Milk Studios in downtown New York City. Founded in 2016, Milk Makeup is built on the values of self-expression and inclusion, captured by its signature “Live Your Look,” and creates vegan, cruelty-free, clean formulas across a portfolio of hero franchises. Milk Makeup is available through milkmakeup.com and retail partners including Sephora, Ulta Beauty and Amazon Premium Beauty in the U.S., and select retailers internationally. For more information, please visit: www.milkmakeup.com.

Forward-Looking Statements

Statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s intention to delist from Nasdaq and to deregister from the SEC, the intended benefits of the delisting and deregistration, the intended rebranding of the business, the allocation of transaction proceeds from the sale of Obagi Medical and future strategies that may be pursued by the Company. These forward-looking statements generally are identified by the words “intends,” “may,” “will,” “future,” “expects,” “anticipates,” “believes,” “seeks,” “targets” and variations of these words or similar expressions (or the negative versions of such words or expressions) and are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: (1) the inability to recognize the anticipated benefits of the delisting and deregistration, including the possibility that the cost savings the Board currently expects are not realized in whole or in part, or are realized more slowly or in lesser amounts than expected; (2) the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities; (3) the overall economic and market conditions and other information about the Company’s possible or assumed future results of operations or performance; (4) changes in general economic conditions; (5) the impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, and foreign currency exchange fluctuations; (6) the ability to implement the Company’s strategic initiatives and continue to innovate its existing products and anticipate and respond to market trends and changes in consumer preferences; (7) the possibility that the Form 25 or the Form 15 is not filed, or does not become effective, on the expected timetable, or that the SEC denies or delays the deregistration; (8) the possibility that no market maker quotes the Class A Ordinary Shares following the delisting, and the resulting reduction in liquidity and in publicly available information regarding the Company; (9) the ability to obtain shareholder approval for the proposed rebranding and to successfully implement the rebranding of the business; and (10) the outcome of the Board’s review of the allocation of transaction proceeds from the sale of Obagi Medical. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 13, 2026, or in other documents that may be filed or furnished by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Waldencast Contact

Investors ICR Allison Malkin waldencastir@icrinc.com

Media ICR Brittany Fraser waldencastpr@icrinc.com

JERICHO, N.Y., Sept. 14, 2026 (GLOBE NEWSWIRE) — Kimco Realty^® (NYSE: KIM) announced today that its management will present at the BofA Securities 2026 Global Real Estate Conference on Tuesday, September 15, 2026.

Event: Kimco Realty^® Management Presentation

When: Tuesday, September 15, 2026, from 12:45 PM – 1:20 PM, ET

Live Webcast: Kimco Realty Management to Present at the BofA Securities 2026 Global Real Estate Conference

Audio from the conference will be available on Kimco Realty’s investor relations website until December 15, 2026.

About Kimco Realty^®

Kimco Realty^® (NYSE: KIM) is a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States. The company’s portfolio is strategically concentrated in the first-ring suburbs of the top major metropolitan markets, including high-barrier-to-entry coastal markets and Sun Belt cities. Its tenant mix is focused on essential, necessity-based goods and services that drive multiple shopping trips per week. Publicly traded on the NYSE since 1991 and included in the S&P 500 Index, the company has specialized in shopping center ownership, management, acquisitions, and value-enhancing redevelopment activities for more than 65 years. With a proven commitment to corporate responsibility, Kimco Realty is a recognized industry leader in this area. As of June 30, 2026, the company owned interests in 564 U.S. shopping centers and mixed-use assets comprising 100 million square feet of gross leasable space.

The company announces material information to its investors using the company’s investor relations website (investors.kimcorealty.com), SEC filings, press releases, public conference calls, and webcasts. The company also uses social media to communicate with its investors and the public, and the information the company posts on social media may be deemed material information. Therefore, the company encourages investors, the media, and others interested in the company to review the information that it posts on the social media channels, including Facebook (www.facebook.com/KimcoRealty), and LinkedIn (www.linkedin.com/company/kimco-realty-corporation). The list of social media channels that the company uses may be updated on its investor relations website from time to time.

CONTACT:
David F. Bujnicki
Senior Vice President, Investor Relations and Strategy
Kimco Realty Corporation
(833) 800-4343
dbujnicki@kimcorealty.com

Net cash provided by operations increased by approximately 250% year-over-year in fiscal 2026

HOBOKEN, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — The Hain Celestial Group, Inc. (Nasdaq: HAIN) (“Hain” or the “Company”), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal fourth quarter and fiscal year ended June 30, 2026. In a separate press release issued today, the Company announced it has reached a definitive agreement to sell its International business.

“Fiscal 2026 was a pivotal year for Hain. We simplified our portfolio, reduced debt, significantly improved free cash flow and exited the year with improving momentum across the business. Our fourth quarter results reflected encouraging sequential improvement, including organic net sales growth in North America, gross margin and adjusted EBITDA margin expansion, and continued progress on productivity and cost discipline initiatives,” stated Alison Lewis, President and CEO.

Lewis continued, “Assuming we successfully complete the transaction announced today to sell our International business and that we reach an agreement with our lenders to extend of our December debt maturity, we would expect to become a more focused North American company with leading brands in attractive categories and a streamlined operating model.”

FINANCIAL HIGHLIGHTS^*

Summary of Fiscal Fourth Quarter Results Compared to the Prior Year Period

• Net sales were $263 million, down 28% year-over-year, driven primarily by the divestiture of our North American snacks business.
  • Organic net sales decreased 2% compared to the prior year period.
    • The decrease in organic net sales was comprised of a 2-point decrease in volume/mix and flat pricing.
• Gross profit margin was 22.5%, a 200-basis point increase from the prior year period.
  • Adjusted gross profit margin was 22.7%, a 230-basis point increase from the prior year period.
• Net loss was $62 million, compared to a net loss of $273 million in the prior year period.
  • Adjusted net loss was $4 million, compared to adjusted net loss of $2 million in the prior year period.
• Adjusted EBITDA was $19 million, compared to $20 million in the prior year period.
• Loss per diluted share was $0.68, compared to a loss per diluted share of $3.06 in the prior year period.
  • Adjusted loss per diluted share was $0.05, compared to adjusted loss per diluted share of $0.02 in the prior year period.

Summary of Fiscal Year 2026 Results Compared to the Prior Year

• Net sales were $1,353 million, down 13% year-over-year.
  • Organic net sales decreased 3% compared to the prior year.
    • The decrease in organic net sales was comprised of a 3-point decrease in volume/mix, partially offset by a 1-point increase in pricing.
• Gross profit margin was 20.1%, a 130-basis point decrease from the prior year.
  • Adjusted gross profit margin was 20.5%, a 100-basis point decrease from the prior year.
• Net loss was $305 million, compared to a net loss of $531 million in the prior year.
  • Adjusted net loss was $16 million, compared to adjusted net income of $8 million in the prior year.
• Adjusted EBITDA was $89 million, compared to $114 million in the prior year.
• Loss per diluted share was $3.36, compared to a loss per diluted share of $5.89 in the prior year.
  • Adjusted loss per diluted share was $0.17, compared to adjusted earnings per diluted share of $0.09 in the prior year.

Cash Flow and Balance Sheet Highlights

• Net cash provided by operating activities was $11 million in the fiscal fourth quarter, compared to net cash used in operating activities of $3 million in the prior year period; net cash provided by operating activities was $78 million in fiscal 2026 compared to $22 million in the prior year.
• Free cash flow was $7 million in the fiscal fourth quarter, compared to an outflow of $9 million in the prior year period; free cash flow was $58 million in fiscal 2026 compared to an outflow of $3 million in the prior year.
• Total debt was $558 million at the end of the fiscal fourth quarter, down from $705 million at the beginning of the fiscal year.
• Net debt was $500 million at the end of the fiscal fourth quarter, compared to $650 million at the beginning of the fiscal year.
• The company ended the fiscal fourth quarter with a net secured leverage ratio of 4.5x as calculated under our credit agreement.

____________________ 
_{*This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. Reconciliations of non-GAAP financial measures to GAAP financial measures and other non-GAAP financial calculations are provided in the tables included in this press release.}

SEGMENT HIGHLIGHTS 

The company operates under two reportable segments: North America and International.

	Net Sales
	Q4 FY26					Q4 FY26 YTD
	$ Millions	Reported Growth Y/Y	M&A/Exit Impact1	FX Impact	Organic Growth Y/Y	$ Millions	Reported Growth Y/Y	M&A/Exit Impact1	FX Impact	Organic Growth Y/Y
North America	112	-46%	-47%	-0%	2%	685	-23%	-23%	0%	0%
International	151	-4%	-1%	1%	-4%	668	-0%	-0%	4%	-4%
Total	263	-28%	-26%	0%	-2%	1,353	-13%	-13%	2%	-3%
* May not add due to rounding
1 Reflects the impact within reported net sales growth of the following items that are excluded from organic net sales growth: net sales from divested brands (ParmCrisps®, Garden Veggie Snacks™, Terra® chips and Garden of Eatin’® snacks brands), held for sale businesses (Personal Care), discontinued brands, and exited product categories.

North America
Fiscal fourth quarter organic net sales increased by 2% year-over-year, primarily driven by growth in meal prep on strength in yogurt, partially offset by lower sales in baby & kids.

Segment gross profit was $34 million and adjusted gross profit was $35 million in the fiscal fourth quarter, representing decreases of 14% and 12%, respectively, from the prior year period. Gross margin was 30.6% and adjusted gross margin was 31.1%, representing increases of 1,140 and 1,190 basis points, respectively, from the prior year period. The increases in margin were primarily driven by an increase in volume / mix and productivity savings, partially offset by cost inflation.

Adjusted EBITDA in the fiscal fourth quarter was $16 million, an increase of 55% compared to the prior year period. The increase was driven primarily by SG&A reduction and productivity savings, partially offset by lower volume/mix and cost inflation. Adjusted EBITDA margin was 14.4% of net sales, a 940-basis point increase compared to the prior year period.

Fiscal 2026 organic net sales were effectively flat year-over-year, as growth in meal prep and beverages was offset by lower sales in baby & kids.

Segment gross profit was $157 million and adjusted gross profit was $162 million in fiscal 2026, representing decreases of 19% and 17%, respectively, from the prior year. Gross margin was 22.9% and adjusted gross margin was 23.7%, representing increases of 120 and 180 basis points, respectively, from the prior year. The increases in margin were primarily driven by productivity savings and pricing, partially offset by cost inflation.

Adjusted EBITDA in fiscal 2026 was $61 million, a decrease of 7% compared to the prior year. The decrease was driven primarily by lower volume / mix and cost inflation, partially offset by productivity savings, reduction in SG&A, and pricing. Adjusted EBITDA margin was 8.9% of net sales, a 160-basis point increase compared to the prior year.

International
Fiscal fourth quarter organic net sales decreased by 4% year-over-year, primarily driven by lower sales in meal prep and baby & kids, partially offset by growth in beverages.

Segment gross profit and adjusted gross profit in the fiscal fourth quarter were both $25 million, each representing a 28% decrease from the prior year period. Gross margin and adjusted gross margin were both 16.6%, each representing a 555-basis point decrease from the prior year period. The decreases in margin were primarily driven by cost inflation, partially offset by productivity savings.

Adjusted EBITDA in the fiscal fourth quarter was $12 million, compared to $21 million in the prior year period, a decrease of 41%. The decrease was primarily driven by cost inflation and lower volume/mix, partially offset by productivity savings. Adjusted EBITDA margin was 8.1% compared to 13.3% in the prior year period.

Fiscal 2026 organic net sales decreased by 4% year-over-year, primarily driven by lower sales in baby & kids and meal prep.

Segment gross profit and adjusted gross profit in fiscal 2026 were both $115 million, each representing an 18% decrease from the prior year. Gross margin and adjusted gross margin were both 17.2%, each representing a 380-basis point decrease from the prior year. The decreases in margin were primarily driven by cost inflation, partially offset by productivity savings.

Adjusted EBITDA in fiscal 2026 was $63 million, compared to $86 million in the prior year, a decrease of 26%. The decrease was primarily driven by cost inflation and lower volume / mix, partially offset by productivity savings and pricing. Adjusted EBITDA margin was 9.5% compared to 12.8% in the prior year.

CATEGORY HIGHLIGHTS

	Net Sales
	Q4 FY26					Q4 FY26 YTD
	$ Millions	Reported Growth Y/Y	M&A/Exit Impact1	FX Impact	Organic Growth Y/Y	$ Millions	Reported Growth Y/Y	M&A/Exit Impact1	FX Impact	Organic Growth Y/Y
Baby & Kids	52	-12%	-1%	0%	-11%	215	-11%	-1%	2%	-12%
Beverages	55	-1%	0%	1%	-2%	256	4%	-0%	4%	1%
Meal Prep	135	-4%	-7%	0%	3%	620	-3%	-5%	3%	0%
Snacks	9	-91%	-84%	0%	-7%	213	-43%	-36%	0%	-7%
Personal Care	12	-19%	n/a	n/a	n/a	49	-21%	n/a	n/a	n/a
Total	263	-28%	-26%	0%	-2%	1,353	-13%	-13%	2%	-3%
* May not add due to rounding
1 Reflects the impact within reported net sales growth of the following items that are excluded from organic net sales growth: net sales from divested brands (ParmCrisps®, Garden Veggie Snacks™, Terra® chips and Garden of Eatin’® snacks brands), held for sale businesses (Personal Care), discontinued brands, and exited product categories.

Baby & Kids
The fiscal fourth quarter organic net sales decline of 11% year-over-year was driven primarily by formula and purees in North America and purees in the UK, partially offset by growth in finger foods in North America.

The fiscal 2026 organic net sales decline of 12% year-over-year was driven primarily by purees in both regions and by formula in North America, partially offset by growth in finger foods and cereal in North America.

Beverages
The fiscal fourth quarter organic net sales decline of 2% year-over-year was due to promotional activity in North America. Fiscal fourth quarter organic net sales grew 3% year-over-year in both tea in North America and in private label non-dairy beverage in Europe.

Fiscal 2026 organic net sales increased by 1% year-over-year driven by tea in North America and private label non-dairy beverage in Europe, partially offset by branded non-dairy beverage in Europe.

Meal Prep
Fiscal fourth quarter organic net sales increased by 3% year-over-year driven primarily by growth in yogurt in North America.

Fiscal 2026 organic net sales were flat year-over-year as growth in yogurt in North America was offset by private label contract losses in spreads & drizzles and softness in plant-based meat internationally.

Snacks
Following the disposition of the North American snacks business, the snacks category is comprised of jellies in the International segment. Organic net sales declined 7% year-over-year in both the fiscal fourth quarter and fiscal 2026.

Conference Call and Webcast Information

Hain Celestial will host a conference call and webcast today at 8:00 AM ET to discuss its results. The live webcast and accompanying presentation are available under the Investors section of the company’s corporate website at www.hain.com. Investors and analysts can access the live call by dialing 833-461-5787 or 585-542-9983. The conference ID is 942039942. Participation by the press and public in the Q&A session will be in listen-only mode. A webcast replay of the call will be available shortly after the conclusion of the live call and archived for one year.

About The Hain Celestial Group, Inc.

Hain Celestial is a leading global health and wellness company whose purpose is to inspire healthier living for people, communities and the planet through better-for-you brands. For more than 30 years, Hain Celestial has intentionally focused on delivering nutrition and well-being that positively impacts today and tomorrow. Headquartered in Hoboken, N.J., Hain Celestial’s products across beverages, yogurt, baby/kids and meal preparation are marketed and sold around the world. Our leading brands include Celestial Seasonings® teas, The Greek Gods® yogurt, Earth’s Best® Organic and Ella’s Kitchen® baby and kids foods, Joya® and Natumi® plant-based beverages, Hartley’s® jelly, as well as Cully & Sully®, Yorkshire Provender®, New Covent Garden® soups, among others. For more information, visit www.hain.com and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. The words “believe,” “expect,” “anticipate,” “may,” “should,” “plan,” “intend,” “potential,” “will” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, among other things, our beliefs or expectations relating to our future performance, results of operations and financial condition; and our strategic initiatives and business strategy, including the pending sale of our International business.

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include: compliance with our credit agreement and our ability to refinance, retire and/or extend the maturity of our existing debt; our ability to execute our business strategy; our ability to complete the pending sale of our International business and manage the challenges and uncertainty facing our remaining business following the sale; challenges and uncertainty resulting from the impact of competition; changes to consumer preferences; our ability to manage our supply chain effectively; input cost inflation, including as a result of tariffs; reliance on independent contract manufacturers; disruption of operations at our manufacturing facilities; customer concentration; reliance on independent distributors; risks associated with operating internationally; risks associated with outsourcing arrangements; risks associated with geopolitical conflicts or events; our reliance on independent certification for a number of our products; our ability to attract and retain highly skilled people; risks related to tax matters; foreign currency exchange risk; general economic conditions; impairments in the carrying value of goodwill or other intangible assets; the reputation of our company and our brands; our ability to use and protect trademarks; cybersecurity incidents; disruptions to information technology systems; pending and future litigation, including litigation relating to Earth’s Best® baby food products; potential liability if our products cause illness or physical harm; the highly regulated environment in which we operate; compliance with data privacy laws; the adequacy of our insurance coverage; climate impacts; liabilities, claims or regulatory change with respect to environmental matters; the potential cessation of our common stock’s listing on The Nasdaq Stock Market LLC; and other risks and matters described in our most recent Annual Report on Form 10-K, our Annual Report on Form 10-K expected to be filed today and our other filings from time to time with the U.S. Securities and Exchange Commission.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures, including, among others, organic net sales; adjusted gross profit and its related margin; adjusted operating income and its related margin; adjusted net (loss) income and its related margin; diluted net (loss) income per common share, as adjusted; adjusted EBITDA and its related margin; free cash flow; and net debt. The reconciliations of historic non-GAAP financial measures to the comparable GAAP financial measures are provided in the tables below. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the company’s consolidated financial statements presented in accordance with GAAP.

We define our non-GAAP financial measures as follows:

• Organic net sales: net sales excluding the impact of acquisitions, divestitures, held for sale businesses, discontinued brands, exited product categories and foreign exchange. To adjust organic net sales for the impact of acquisitions, the net sales of an acquired business are excluded from fiscal quarters constituting or falling within the current period and prior period where the applicable fiscal quarter in the prior period did not include the acquired business for the entire quarter. To adjust organic net sales for the impact of divestitures, held for sale businesses, discontinued brands and exited product categories, the net sales of a divested business, held for sale business, discontinued brand or exited product category are excluded from all periods. To adjust organic net sales for the impact of foreign exchange, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year.
• Adjusted gross profit and its related margin: gross profit, before plant closure related costs, net and warehouse and manufacturing consolidation and other costs, net.
• Adjusted operating income and its related margin: operating loss before goodwill impairment, costs associated with acquisitions, divestitures and other transactions, productivity and transformation costs, certain litigation expenses, net, long-lived asset and intangibles impairment, plant closure related costs, net, proceeds from insurance claim, CEO succession costs, warehouse and manufacturing consolidation and other costs, net.
• Adjusted net (loss) income and its related margin and diluted net (loss) income per common share, as adjusted: net loss, adjusted to exclude the impact of goodwill impairment, costs associated with acquisitions, divestitures and other transactions, productivity and transformation costs, certain litigation expenses, net, long-lived asset and intangibles impairment, plant closure related costs, net, proceeds from insurance claim, CEO succession costs, warehouse and manufacturing consolidation and other costs, net , unrealized currency losses, loss (gain) on sales of assets, and the related tax effects of such adjustments.
• Adjusted EBITDA and its related margin: net loss before depreciation and amortization, equity in net loss of equity-method investees, net interest expense, income taxes, stock-based compensation, net, unrealized currency losses, certain litigation expenses, net, proceeds from insurance claim, productivity and transformation costs, plant closure related costs, net, warehouse and manufacturing consolidation and other costs, net, CEO succession costs, costs associated with acquisitions, divestitures and other transactions, loss (gain) on sales of assets, goodwill impairment and long-lived asset and intangibles impairment. 
• Free cash flow: net cash provided by (used in) operating activities less purchases of property, plant and equipment.
• Net debt: total debt less cash and cash equivalents.

We believe that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the company’s operations and are useful for period-over-period comparisons of operations. We provide:

• Organic net sales to demonstrate the growth rate of net sales excluding the impact of acquisitions, divestitures, held for sale businesses, discontinued brands, and exited product categories and foreign exchange, and believe organic net sales is useful to investors because it enables them to better understand the growth of our business from period to period.
• Adjusted results as important supplemental measures of our performance and believe they are frequently used by securities analysts, investors and other interested parties in the evaluation of our Company and companies in our industry.
• Free cash flow as one factor in evaluating the amount of cash available for discretionary investments.
• Net debt as a useful measure to monitor leverage and evaluate the balance sheet.

We discuss the Company’s net secured leverage ratio as calculated under our credit agreement as a measure of our financial condition, liquidity and compliance with our credit agreement. For a description of the material terms of our credit agreement and risks of non-compliance with our credit agreement, see “Liquidity and Capital Resources” under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K expected to be filed today and our other filings from time to time with the U.S. Securities and Exchange Commission.

Investor Relations Contact:
Alexis Tessier
Investor.Relations@hain.com

Media Contact:
Justin Godley
Justin.Godley@hain.com

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(unaudited and in thousands, except per share amounts)
	Fourth Quarter								Fourth Quarter Year to Date
	2026				2025				2026				2025
Net sales	$	263,069			$	363,348			$	1,353,429			$	1,559,780
Cost of sales		203,866				289,002				1,081,317				1,225,722
Gross profit		59,203				74,346				272,112				334,058
Selling, general and administrative expenses		62,546				67,416				248,039				271,833
Goodwill impairment		42,293				227,364				193,219				428,882
Amortization of acquired intangible assets		5,077				1,300				10,802				6,476
Productivity and transformation costs		4,520				5,033				22,039				21,530
Long-lived asset and intangibles impairment		430				24,911				27,394				66,940
Proceeds from insurance claim		–				–				(25,900	)			–
Operating loss		(55,663	)			(251,678	)			(203,481	)			(461,603	)
Interest and other financing expense, net		11,882				12,841				56,957				51,253
Other (income) expense, net		(1,523	)			(1,559	)			46,342				875
Loss before income taxes and equity in net loss of equity-method investees		(66,022	)			(262,960	)			(306,780	)			(513,731	)
(Benefit) provision for income taxes		(4,097	)			9,551				(2,208	)			15,297
Equity in net loss of equity-method investees		24				104				351				1,813
Net loss	$	(61,949	)		$	(272,615	)		$	(304,923	)		$	(530,841	)
Net loss per common share:
Basic	$	(0.68	)		$	(3.06	)		$	(3.36	)		$	(5.89	)
Diluted	$	(0.68	)		$	(3.06	)		$	(3.36	)		$	(5.89	)
Shares used in the calculation of net loss per common share:
Basic		90,996				89,024				90,736				90,127
Diluted		90,996				89,024				90,736				90,127

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(unaudited and in thousands)
	June 30, 2026				June 30, 2025
ASSETS
Current assets:
Cash and cash equivalents	$	58,078			$	54,355
Accounts receivable, net		121,022				154,440
Inventories		149,275				248,731
Prepaid expenses and other current assets		82,017				43,169
Assets held for sale		5,882				29,603
Total current assets		416,274				530,298
Property, plant and equipment, net		184,665				264,730
Goodwill		246,079				500,961
Trademarks and other intangible assets, net		173,520				210,905
Operating lease right-of-use assets, net		49,057				71,171
Other assets		20,788				25,213
Total assets	$	1,090,383			$	1,603,278
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	125,497			$	188,307
Accrued expenses and other current liabilities		143,560				68,426
Current portion of long-term debt		557,552				7,653
Liabilities related to assets held for sale		4,153				12,987
Total current liabilities		830,762				277,373
Long-term debt, less current portion		292				697,168
Deferred income taxes		32,930				40,332
Operating lease liabilities, noncurrent portion		44,409				65,284
Other noncurrent liabilities		27,195				48,116
Total liabilities		935,588				1,128,273
Stockholders’ equity:
Common stock		1,135				1,125
Additional paid-in capital		1,243,863				1,238,402
Retained (deficit) earnings		(258,245	)			46,678
Accumulated other comprehensive loss		(101,463	)			(81,053	)
		885,290				1,205,152
Less: Treasury stock		(730,495	)			(730,147	)
Total stockholders’ equity		154,795				475,005
Total liabilities and stockholders’ equity	$	1,090,383			$	1,603,278

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(unaudited and in thousands)
	Fourth Quarter								Fourth Quarter Year to Date
	2026				2025				2026				2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(61,949	)		$	(272,615	)		$	(304,923	)		$	(530,841	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization		13,508				11,357				52,552				44,259
Deferred income taxes		(5,759	)			(1,798	)			(8,446	)			(4,423	)
Equity in net loss of equity-method investees		24				104				351				1,813
Stock-based compensation, net		1,279				(1,273	)			5,471				8,149
Goodwill impairment		42,293				227,364				193,219				428,882
Long-lived asset and intangibles impairment		430				24,911				27,394				66,940
Loss (gain) on sale of assets		209				(5,396	)			48,710				(3,194	)
Other non-cash items, net		718				1,365				3,589				2,138
Increase (decrease) in cash attributable to changes in operating assets and liabilities:
Accounts receivable		18,165				26,565				35,806				25,204
Inventories		13,378				7,251				72,934				(3,354	)
Other current assets		2,148				11,393				(37,621	)			3,114
Other assets and liabilities		(129	)			1,881				(4,138	)			1,320
Accounts payable and accrued expenses		(12,872	)			(33,757	)			(6,629	)			(17,892	)
Net cash provided by (used in) operating activities		11,443				(2,648	)			78,269				22,115
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment		(4,609	)			(6,224	)			(20,613	)			(25,284	)
Proceeds from sale of assets, net		(204	)			197				102,566				13,970
Investments and joint ventures, including proceeds from dispositions		–				10,000				–				12,570
Proceeds from termination of net investment hedges		–				–				–				2,363
Net cash (used in) provided by investing activities		(4,813	)			3,973				81,953				3,619
CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings under bank revolving credit facility		34,000				65,000				190,000				221,000
Repayments under bank revolving credit facility		(24,000	)			(59,500	)			(229,500	)			(245,500	)
Repayments under term loan		(1,875	)			(9,375	)			(108,600	)			(15,000	)
Payments of other debt, net		(24	)			(3,503	)			(2,666	)			(3,524	)
Employee shares withheld for taxes		(5	)			(33	)			(348	)			(1,414	)
Proceeds from termination of fair value hedge		–				–				–				552
Net cash provided by (used in) financing activities		8,096				(7,411	)			(151,114	)			(43,886	)
Effect of exchange rate changes on cash		(959	)			16,016				(5,385	)			18,200
Net increase in cash and cash equivalents		13,767				9,930				3,723				48
Cash and cash equivalents at beginning of period		44,311				44,425				54,355				54,307
Cash and cash equivalents at end of period	$	58,078			$	54,355			$	58,078			$	54,355

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Net Sales, Gross Profit and Adjusted EBITDA by Segment
(unaudited and in thousands)
	North America				International				Corporate/Other				Hain Consolidated
Net Sales
Net sales – Q4 FY26	$	111,817			$	151,252			$	–			$	263,069
Net sales – Q4 FY25	$	205,790			$	157,558			$	–			$	363,348
% change – FY26 net sales vs. FY25 net sales		(45.7	)%			(4.0	)%							(27.6	)%
Gross Profit
Q4 FY26
Gross profit	$	34,161			$	25,042			$	–			$	59,203
Non-GAAP adjustments(1)		580				–				–				580
Adjusted gross profit	$	34,741			$	25,042			$	–			$	59,783
% change – FY26 gross profit vs. FY25 gross profit		(13.6	)%			(28.1	)%							(20.4	)%
% change – FY26 adjusted gross profit vs. FY25 adjusted gross profit		(12.1	)%			(28.1	)%							(19.6	)%
Gross margin		30.6	%			16.6	%							22.5	%
Adjusted gross margin		31.1	%			16.6	%							22.7	%
Q4 FY25
Gross profit	$	39,522			$	34,824			$	–			$	74,346
Non-GAAP adjustments(1)		(15	)			–				–				(15	)
Adjusted gross profit	$	39,507			$	34,824			$	–			$	74,331
Gross margin		19.2	%			22.1	%							20.5	%
Adjusted gross margin		19.2	%			22.1	%							20.5	%
Adjusted EBITDA
Q4 FY26
Adjusted EBITDA	$	16,145			$	12,324			$	(9,727	)		$	18,742
% change – FY26 Adjusted EBITDA vs. FY25 Adjusted EBITDA		55.3	%			(41.1	)%			14.9	%			(5.8	)%
Adjusted EBITDA margin		14.4	%			8.1	%							7.1	%
Q4 FY25
Adjusted EBITDA	$	10,398			$	20,938			$	(11,430	)		$	19,906
Adjusted EBITDA margin		5.1	%			13.3	%							5.5	%
(1)See accompanying table “Adjusted Gross Profit, Adjusted Operating Income, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share”

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Net Sales, Gross Profit and Adjusted EBITDA by Segment
(unaudited and in thousands)
	North America				International				Corporate/Other				Hain Consolidated
Net Sales
Net sales – Q4 FY26 YTD	$	685,053			$	668,376			$	–			$	1,353,429
Net sales – Q4 FY25 YTD	$	888,626			$	671,154			$	–			$	1,559,780
% change – FY26 net sales vs. FY25 net sales		(22.9	)%			(0.4	)%							(13.2	)%
Gross Profit
Q4 FY26 YTD
Gross profit	$	156,895			$	115,217			$	–			$	272,112
Non-GAAP adjustments(1)		5,382				–				–				5,382
Adjusted gross profit	$	162,277			$	115,217			$	–			$	277,494
% change – FY26 gross profit vs. FY25 gross profit		(18.7	)%			(18.4	)%							(18.5	)%
% change – FY26 adjusted gross profit vs. FY25 adjusted gross profit		(16.6	)%			(18.4	)%							(17.4	)%
Gross margin		22.9	%			17.2	%							20.1	%
Adjusted gross margin		23.7	%			17.2	%							20.5	%
Q4 FY25 YTD
Gross profit	$	192,910			$	141,148			$	–			$	334,058
Non-GAAP adjustments(1)		1,764				–				–				1,764
Adjusted gross profit	$	194,674			$	141,148			$	–			$	335,822
Gross margin		21.7	%			21.0	%							21.4	%
Adjusted gross margin		21.9	%			21.0	%							21.5	%
Adjusted EBITDA
Q4 FY26 YTD
Adjusted EBITDA	$	61,236			$	63,458			$	(35,686	)		$	89,008
% change – FY26 Adjusted EBITDA vs. FY25 Adjusted EBITDA		(6.5	)%			(26.2	)%			5.3	%			(21.8	)%
Adjusted EBITDA margin		8.9	%			9.5	%							6.6	%
Q4 FY25 YTD
Adjusted EBITDA	$	65,470			$	86,000			$	(37,681	)		$	113,789
Adjusted EBITDA margin		7.4	%			12.8	%							7.3	%
(1)See accompanying table “Adjusted Gross Profit, Adjusted Operating Income, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share”

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Adjusted Gross Profit, Adjusted Operating Income, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share
(unaudited and in thousands, except per share amounts)
Reconciliation of Gross Profit, GAAP to Gross Profit, as Adjusted:
	Fourth Quarter								Fourth Quarter Year to Date
	2026				2025				2026				2025
Gross profit, GAAP	$	59,203			$	74,346			$	272,112			$	334,058
Adjustments to Cost of sales:
Plant closure related costs, net		580				(15	)			5,382				1,380
Warehouse/manufacturing consolidation and other costs, net		–				–				–				384
Gross profit, as adjusted	$	59,783			$	74,331			$	277,494			$	335,822
Reconciliation of Operating Loss, GAAP to Operating Income, as Adjusted:
	Fourth Quarter								Fourth Quarter Year to Date
	2026				2025				2026				2025
Operating loss, GAAP	$	(55,663	)		$	(251,678	)		$	(203,481	)		$	(461,603	)
Adjustments to Cost of sales:
Plant closure related costs, net		580				(15	)			5,382				1,380
Warehouse/manufacturing consolidation and other costs, net		–				–				–				384
Adjustments to Operating expenses(a):
Goodwill impairment		42,293				227,364				193,219				428,882
Transaction and integration costs, net		9,390				86				14,125				(488	)
Productivity and transformation costs		4,520				5,033				22,039				21,530
Certain litigation expenses, net(b)		1,703				1,219				4,867				3,473
Long-lived asset and intangibles impairment		430				24,911				27,394				66,940
Plant closure related costs, net		93				1				374				(165	)
Proceeds from insurance claim(c)		–				–				(25,900	)			–
CEO succession		–				4,774				–				4,774
Operating income, as adjusted	$	3,346			$	11,695			$	38,019			$	65,107
Reconciliation of Net Loss, GAAP to Net (Loss) Income, as Adjusted:
	Fourth Quarter								Fourth Quarter Year to Date
	2026				2025				2026				2025
Net loss, GAAP	$	(61,949	)		$	(272,615	)		$	(304,923	)			(530,841	)
Adjustments to Cost of sales:
Plant closure related costs, net		580				(15	)			5,382				1,380
Warehouse/manufacturing consolidation and other costs, net		–				–				–				384
Adjustments to Operating expenses(a):
Goodwill impairment		42,293				227,364				193,219				428,882
Transaction and integration costs, net		9,390				86				14,125				(488	)
Productivity and transformation costs		4,520				5,033				22,039				21,530
Certain litigation expenses, net(b)		1,703				1,219				4,867				3,473
Long-lived asset and intangibles impairment		430				24,911				27,394				66,940
Plant closure related costs, net		93				1				374				(165	)
Proceeds from insurance claim(c)		–				–				(25,900	)			–
CEO succession		–				4,774				–				4,774
Adjustments to Interest and other expense (income), net(d):
Unrealized currency losses		328				3,116				951				3,941
Loss (gain) on sale of assets		209				(5,396	)			48,710				(3,194	)
Adjustments to (Benefit) provision for income taxes:
Net tax impact of non-GAAP adjustments		(1,992	)			9,838				(1,859	)			11,453
Net (loss) income, as adjusted	$	(4,395	)		$	(1,684	)		$	(15,621	)			8,069
Net loss margin		(23.5	)%			(75.0	)%			(22.5	)%			(34.0	)%
Adjusted net (loss) income margin		(1.7	)%			(0.5	)%			(1.2	)%			0.5	%
Diluted shares used in the calculation of net loss per common share:		90,996				89,024				90,736				90,127
Diluted shares used in the calculation of adjusted net (loss) income per common share:		90,996				89,024				90,736				90,380
Diluted net loss per common share, GAAP	$	(0.68	)		$	(3.06	)		$	(3.36	)		$	(5.89	)
Diluted net (loss) income per common share, as adjusted	$	(0.05	)		$	(0.02	)		$	(0.17	)		$	0.09
(a) Operating expenses include amortization of acquired intangibles, selling, general and administrative expenses, productivity and transformation costs, long-lived asset and intangibles impairment and goodwill impairment.
(b) Expenses and items relating to securities class action, baby food litigation and SEC investigation.
(c) Represents a receivable under the Company’s representation and warranty insurance related to one of its prior acquisitions, which was collected on January 2, 2026.
(d) Interest and other expense (income), net includes interest and other financing expenses, net, unrealized currency losses, loss (gain) on sale of assets and other expense, net.

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Organic Net Sales Growth by Segment
(unaudited and in thousands)
Q4 FY26	North America				International				Hain Consolidated
Net sales	$	111,817			$	151,252			$	263,069
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		14,056				731				14,787
Less: Impact of foreign currency exchange		(18	)			1,596				1,578
Organic net sales	$	97,779			$	148,925			$	246,704
Q4 FY25
Net sales	$	205,790			$	157,558			$	363,348
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		109,615				2,475				112,090
Organic net sales	$	96,175			$	155,083			$	251,258
Net sales decline		(45.7	)%			(4.0	)%			(27.6	)%
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		(47.4	)%			(1.0	)%			(26.2	)%
Less: Impact of foreign currency exchange		(0.0	)%			1.0	%			0.4	%
Organic net sales growth (decline)		1.7	%			(4.0	)%			(1.8	)%
Q4 FY26 YTD	North America				International				Hain Consolidated
Net sales	$	685,053			$	668,376			$	1,353,429
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		252,165				5,659				257,824
Less: Impact of foreign currency exchange		249				29,363				29,612
Organic net sales	$	432,639			$	633,354			$	1,065,993
Q4 FY25 YTD
Net sales	$	888,626			$	671,154			$	1,559,780
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		456,786				9,251				466,037
Organic net sales	$	431,840			$	661,903			$	1,093,743
Net sales decline		(22.9	)%			(0.4	)%			(13.2	)%
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		(23.1	)%			(0.5	)%			(12.6	)%
Less: Impact of foreign currency exchange		0.0	%			4.4	%			1.9	%
Organic net sales growth (decline)		0.2	%			(4.3	)%			(2.5	)%

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Organic Net Sales Growth by Category
(unaudited and in thousands)
Q4 FY26	Baby & Kids				Beverages				Meal Prep				Snacks				Personal Care				Hain Consolidated
Net sales	$	52,313			$	55,370			$	135,004			$	8,515			$	11,867			$	263,069
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		167				–				1,444				1,309				11,867				14,787
Less: Impact of foreign currency exchange		203				778				569				28				–				1,578
Organic net sales	$	51,943			$	54,592			$	132,991			$	7,178			$	–			$	246,704
Q4 FY25
Net sales	$	59,327			$	55,783			$	140,196			$	93,324			$	14,718			$	363,348
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		879				42				10,852				85,599				14,718				112,090
Organic net sales	$	58,448			$	55,741			$	129,344			$	7,725			$	–			$	251,258
Net sales decline		(11.8	)%			(0.7	)%			(3.7	)%			(90.9	)%			(19.4	)%			(27.6	)%
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		(1.0	)%			0.0	%			(6.9	)%			(83.8	)%		n/a					(26.2	)%
Less: Impact of foreign currency exchange		0.3	%			1.4	%			0.4	%			0.0	%		n/a					0.4	%
Organic net sales (decline) growth		(11.1	)%			(2.1	)%			2.8	%			(7.1	)%		n/a					(1.8	)%
Q4 FY26 YTD	Baby & Kids				Beverages				Meal Prep				Snacks				Personal Care				Hain Consolidated
Net sales	$	214,828			$	255,979			$	620,121			$	213,208			$	49,293			$	1,353,429
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		2,849				32				20,732				184,918				49,293				257,824
Less: Impact of foreign currency exchange		3,667				8,897				16,013				1,035				–				29,612
Organic net sales	$	208,312			$	247,050			$	583,376			$	27,255			$	–			$	1,065,993
Q4 FY25 YTD
Net sales	$	241,552			$	245,147			$	639,507			$	371,012			$	62,562			$	1,559,780
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		5,291				145				56,252				341,787				62,562				466,037
Organic net sales	$	236,261			$	245,002			$	583,255			$	29,225			$	–			$	1,093,743
Net sales (decline) growth		(11.1	)%			4.4	%			(3.0	)%			(42.5	)%			(21.2	)%			(13.2	)%
Less: Impact of divestitures, held for sale businesses, discontinued brands and exited product categories		(0.8	)%			(0.0	)%			(5.5	)%			(36.1	)%		n/a					(12.6	)%
Less: Impact of foreign currency exchange		1.5	%			3.6	%			2.5	%			0.3	%		n/a					1.9	%
Organic net sales (decline) growth		(11.8	)%			0.8	%			0.0	%			(6.7	)%		n/a					(2.5	)%

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Adjusted EBITDA
(unaudited and in thousands)
	Fourth Quarter								Fourth Quarter Year to Date
	2026				2025				2026				2025
Net loss	$	(61,949	)		$	(272,615	)		$	(304,923	)		$	(530,841	)
Depreciation and amortization		13,508				11,357				52,552				44,259
Equity in net loss of equity-method investees		24				104				351				1,813
Interest expense, net		10,431				11,689				50,154				47,773
(Benefit) provision for income taxes		(4,097	)			9,551				(2,208	)			15,297
Stock-based compensation, net		1,279				(1,273	)			5,471				8,149
Unrealized currency losses		328				3,116				951				3,823
Certain litigation expenses, net(a)		1,703				1,219				4,867				3,473
Proceeds from insurance claim(b)		–				–				(25,900	)			–
Restructuring activities
Productivity and transformation costs		4,520				5,033				22,039				21,530
Plant closure related costs, net		673				(14	)			2,206				1,215
Warehouse/manufacturing consolidation and other costs, net		–				–				–				384
CEO succession		–				4,774				–				4,774
Acquisitions, divestitures and other
Transaction and integration costs, net		9,390				86				14,125				(488	)
Loss (gain) on sale of assets		209				(5,396	)			48,710				(3,194	)
Impairment charges
Goodwill impairment		42,293				227,364				193,219				428,882
Long-lived asset and intangibles impairment		430				24,911				27,394				66,940
Adjusted EBITDA	$	18,742			$	19,906			$	89,008			$	113,789
(a) Expenses and items relating to securities class action, baby food litigation and SEC investigation.
(b) Represents a receivable under the Company’s representation and warranty insurance related to one of its prior acquisitions, which was collected on January 2, 2026.

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Free Cash Flow
(unaudited and in thousands)
	Fourth Quarter								Fourth Quarter Year to Date
	2026				2025				2026				2025
Net cash provided by (used in) operating activities	$	11,443			$	(2,648	)		$	78,269			$	22,115
Purchases of property, plant and equipment		(4,609	)			(6,224	)			(20,613	)			(25,284	)
Free cash flow	$	6,834			$	(8,872	)		$	57,656			$	(3,169	)

THE HAIN CELESTIAL GROUP, INC. AND SUBSIDIARIES
Net Debt
(unaudited and in thousands)
	June 30, 2026			June 30, 2025
Debt
Current portion of long-term debt	$	557,552		$	7,653
Long-term debt, less current portion		292			697,168
Total debt		557,844			704,821
Less: Cash and cash equivalents		58,078			54,355
Net debt	$	499,766		$	650,466